The global advanced therapy medicinal products (ATMP) CDMO market is on an impressive growth trajectory. Valued at USD 6.73 billion in 2024, it is projected to soar to USD 37.27 billion by 2034, growing at a CAGR of 18.82% from 2025 to 2034. This surge is fueled by an increasing number of rare diseases, infectious disease outbreaks, and a robust pipeline of ATMPs in clinical trials. Advancements in gene editing technologies like CRISPR, rising pharmaceutical R&D investments, and digital innovations such as AI-driven analytics are also accelerating market growth.
This article highlights the key companies shaping the ATMP CDMO landscape, alongside market trends and future prospects.
2024 Market Size: USD 6.73 billion
2034 Projected Size: USD 37.27 billion
CAGR (2025–2034): 18.82%
Top Region (2024): North America (45–50% share)
Fastest Growing Region: Asia Pacific (2025–2034)
Leading Segment (2024): Cell therapy products (35–38% revenue share)
Fastest Growing Segment: Gene therapy products
About: A global leader in contract development and manufacturing, AGC Biologics specializes in cell and gene therapy, with a strong presence in biologics manufacturing.
Products: Viral vectors, cell therapies, plasmid DNA production.
Market Cap: Approx. USD 3.2 billion.
About: Known for its high-quality plasmid DNA, RNA, and proteins, Aldevron serves biopharma and research markets globally.
Products: Custom plasmid DNA, mRNA, proteins for cell and gene therapies.
Market Cap: Parent Danaher’s market cap exceeds USD 190 billion.
About: A leading CDMO focusing on viral vector production, Andelyn supports clinical and commercial development for ATMPs.
Products: Adeno-associated virus (AAV), lentivirus production services.
Market Cap: Privately held; estimated annual revenue USD 150M+.
About: Offers regulatory consulting and development support for advanced therapies.
Products: Regulatory affairs, quality assurance, market authorization services.
Market Cap: Part of PharmaLex Group with estimated value USD 1.1 billion.
About: Specializes in viral vector manufacturing for gene therapies, acquired by Thermo Fisher in 2019.
Products: Clinical and commercial viral vector manufacturing.
Market Cap: Thermo Fisher’s market cap is over USD 220 billion.
About: Provides integrated services for gene therapy development from discovery to commercial launch.
Products: Plasmid DNA, viral vector manufacturing, cell therapy solutions.
Market Cap: Approx. USD 10.5 billion.
About: A full-service CDMO dedicated to accelerating cell and gene therapy programs.
Products: Viral vectors, cell processing, plasmid DNA manufacturing.
Market Cap: Privately held; projected valuation USD 500M+.
About: A trusted partner for biopharma companies, offering preclinical, clinical, and CDMO services.
Products: Plasmids, viral vectors, biologics testing solutions.
Market Cap: Approx. USD 12.8 billion.
About: A prominent player in bioprocessing technologies and solutions for ATMP manufacturing.
Products: Bioprocess equipment, viral vectors, custom manufacturing.
Market Cap: Included under Danaher’s USD 190 billion valuation.
About: Provides end-to-end services for biologics and ATMPs from development to commercialization.
Products: Cell & gene therapy services, bioanalytics, process development.
Market Cap: Approx. USD 13.4 billion.
About: Offers contract development and manufacturing services for biologics and advanced therapies.
Products: Gene therapies, cell therapies, process development.
Market Cap: Parent Fujifilm’s market cap is approx. USD 50 billion.
About: One of the largest CDMOs globally, Lonza is a key partner in ATMP manufacturing.
Products: Viral vectors, cell therapies, bioprocessing solutions.
Market Cap: Approx. USD 40 billion.
About: Focused on cell and gene therapies, Minaris offers global manufacturing solutions.
Products: Autologous and allogeneic cell therapy manufacturing.
Market Cap: Privately held; annual revenue estimated USD 250M+.
About: Specializes in purification and production solutions for ATMPs.
Products: Viral vectors, bio-manufacturing services.
Market Cap: Privately owned; estimated value USD 800M+.
About: A leading gene and cell therapy company providing CDMO services worldwide.
Products: Lentiviral vectors, cell and gene therapy process development.
Market Cap: Approx. USD 600 million.
About: A China-based CDMO specializing in cell and gene therapy solutions.
Products: Viral vectors, cell processing services, regulatory support.
Market Cap: Parent company Porton Pharma Solutions’ market cap is USD 2.3 billion.
About: A pioneer in cell therapy manufacturing, supporting development from clinical to commercial scale.
Products: Cell therapy manufacturing, process development.
Market Cap: Privately held; revenue around USD 50M+.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
Q1: What are Advanced Therapy Medicinal Products (ATMPs)?
ATMPs include gene therapy, cell therapy, and tissue-engineered products designed to treat rare and complex diseases.
Q2: Why is the ATMP CDMO market growing so rapidly?
The rise in rare diseases, advanced gene-editing tools like CRISPR, and high investments in biopharma R&D are major growth drivers.
Q3: Which region dominates the ATMP CDMO market?
North America leads with nearly 50% market share, while Asia Pacific is the fastest-growing region.
Q4: Who are the top players in the ATMP CDMO industry?
Companies like Lonza, Catalent, Thermo Fisher, Fujifilm Diosynth Biotechnologies, and AGC Biologics are key leaders.
Q5: What is the projected CAGR for the ATMP CDMO market?
The market is expected to grow at a CAGR of 18.82% between 2025 and 2034.
Source : https://www.towardshealthcare.com/insights/advanced-therapy-medicinal-products-cdmo-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5868
🏥 Rapid Expansion of the Medical Device Sector Asia-Pacific’s orthopedic device market medical industry is experiencing an unprecedented boom. From… Read More
The global orthopedic device markett is witnessing transformative growth, fueled by technological advancements, an aging population, and rising demand for… Read More
North America seized 42% of the generative AI in life science market share in 2024. But what fueled this dominance?… Read More
San Diego, CA, July 18, 2025 Acadia Pharmaceuticals, a leader in treatments for neurological and rare diseases, has unveiled an… Read More
Warsaw, IN, July 18, 2025 – Zimmer Biomet Holdings, Inc., a leading innovator in medical technology, has announced a definitive… Read More
London, July 18, 2025 – ViiV Healthcare, a global leader in HIV-focused pharmaceutical innovation, unveiled data from its Phase 3b… Read More